Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 3

3(37.5%)

Phase 4

2(25.0%)

N/A

1(12.5%)

Phase 2

1(12.5%)

Phase 1

1(12.5%)

8Total

Phase 3(3)

Phase 4(2)

N/A(1)

Phase 2(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05960929Phase 3Recruiting

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

Role: lead

NCT03058666Phase 3Completed

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

Role: lead

NCT03582930Unknown

Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)

Role: lead

NCT04056741Phase 2Suspended

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

Role: lead

NCT02164734Phase 4Terminated

Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome

Role: collaborator

NCT00569530Phase 3Completed

Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide

Role: collaborator

NCT03748173Phase 1Terminated

Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04

Role: lead

NCT01042600Phase 4Completed

Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation

Role: collaborator

NCT00599651Not ApplicableTerminated

Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)

Role: collaborator

All 9 trials loaded